Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBT Margin (2020 - 2025)

Cytek Biosciences' EBT Margin history spans 6 years, with the latest figure at 6.49% for Q4 2025.

  • For Q4 2025, EBT Margin fell 2445.0% year-over-year to 6.49%; the TTM value through Dec 2025 reached 14.81%, down 1197.0%, while the annual FY2025 figure was 14.81%, 1197.0% down from the prior year.
  • EBT Margin reached 6.49% in Q4 2025 per CTKB's latest filing, up from 14.86% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 17.96% in Q4 2024 to a low of 27.18% in Q1 2025.
  • Average EBT Margin over 5 years is 5.14%, with a median of 4.99% recorded in 2025.
  • Peak YoY movement for EBT Margin: skyrocketed 1202bps in 2021, then plummeted -2445bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 0.51% in 2021, then surged by 1765bps to 8.51% in 2022, then decreased by -17bps to 7.06% in 2023, then surged by 154bps to 17.96% in 2024, then crashed by -136bps to 6.49% in 2025.
  • Per Business Quant, the three most recent readings for CTKB's EBT Margin are 6.49% (Q4 2025), 14.86% (Q3 2025), and 14.86% (Q2 2025).